Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400

Phase 2EDG-15400Positive

AI Analysis

Summary

Edgewise Therapeutics has dosed the first patient in the Phase 2 EQUINOX-HFpEF trial evaluating EDG-15400 in adults with symptomatic heart failure with preserved ejection fraction. The company will present trial design and Phase 1 data at HFSA 2026.

Clinical Trial Data

Phase

Phase 2

Outcome Details

First patient dosed in Phase 2 EQUINOX-HFpEF trial

Importance:6/10

Sentiment:

0.60

Phase 2HFpEFcardiactrial initiationEDG-15400

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on October 8, 2026 12:00 PM

Read Original